GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
|
|
- Morris Charles
- 5 years ago
- Views:
Transcription
1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. GSK Medicine: GSK (formerly ) Study Number: (Bristol-Myers Squibb [BMS] Study Number: AI46838) Title: A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy and Doseresponse of /GSK , Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 Infected Adults Rationale: Existing antiretroviral (ARV) therapies have safety (both short and longer term) and tolerability associated concerns. This study was conducted to evaluate the efficacy of three doses of /GSK (a novel second generation human immunodeficiency virus [HIV] maturation inhibitor) when given in combination with tenofovir/emtricitabine (). This study was to provide supportive data to select a safe and therapeutic dose of /GSK for subsequent development. NOTE: ViiV Healthcare (VH) purchased the HIV portfolio from Bristol-Myers Squibb (BMS) in February 216. This included the Maturation Inhibitor GSK (formerly known as ). Phase: 2b Study Period: 28-Jan-215 to 26-May-216 Study Design: This was a randomized, active-controlled, double-blind clinical trial. Subjects were randomized 1:1:1:1 to one of four different treatment arms. The study consisted of Screening, Baseline visit (Day 1), optional Week 2 intensive pharmacokinetic (PK) Visit, Visits Week 4 Week 96, and a follow-up visit. The study ended early after Week 24 for virologic resistance and gastrointestinal (GI) intolerability. Centres: 58 centres in 12 countries (United States [9 centres], Germany [7 centres], Canada [6 centres], Spain [6 centres], Argentina [5 centres], France [5 centres], Italy [4 centres], Mexico [4 centres], South Africa [4 centres], Chile [3 centres], Poland [3 centres], and United Kingdom [2 centres]). Indication: Human Immunodeficiency Virus Infection Treatment: Subjects were to receive 6 milligrams (mg) once daily (QD)+ 3/2 mg QD; or 12 mg QD+ 3/2 mg QD; or 18 mg QD+ 3/2 mg QD; or efavirenz (EFV) 6 mg QD+ 3/2 mg QD for a duration of 96 weeks. Objectives: To evaluate antiviral efficacy of 3 doses (6, 12 and 18 mg) of /GSK , and EFV, each when given in combination with tenofovir/emtricitabine () by determining the proportion of treatmentnaïve subjects with plasma HIV-1 RNA <4 copies per millilitre (c/ml) at Week 24 Primary Endpoint/Efficacy: The primary endpoint was the proportion of subjects with plasma HIV-1 RNA <4 c/ml at Week 24. Secondary Outcome (Endpoints)/Efficacy: The antiviral efficacy was to be determined by the proportion of subjects with plasma HIV-1 ribonucleic acid (RNA) <4 c/ml at Weeks 48 and 96 using the Food and Drug Administration (FDA) snapshot algorithm The antiviral efficacy was also to be assessed by the proportion of subjects with plasma HIV-1 RNA <2 c/ml at Weeks 24, 48, and 96 using the FDA snapshot algorithm approach with positive response defined as HIV-1 RNA <2 c/ml The emergence of HIV drug resistance among samples selected for drug resistance testing was to be assessed using the most recent version of the International acquired immune deficiency syndrome (AIDS) Society (IAS- USA) list of HIV-1 drug resistance mutations Changes from baseline in log1 HIV-1 RNA and in cluster of differentiation 4 (CD4)+ cell counts and changes in the percentage of CD4+ cells over time were to be assessed using on-treatment laboratory results and prespecified visit windows The frequency of serious adverse events (SAEs) and adverse events (AEs) leading to discontinuation (DC) were tabulated directly from the case report forms (CRFs). The summary counted the number of subjects that have at least one event. The occurrence of new AIDS defining events (Centers for Disease Control and Prevention [CDC] Class C events) were to be tabulated from the CRFs. The summary counted the number of subjects that have at least one event. The steady-state plasma PK of /GSK was to be assessed using the intensive PK data, collected at Week 2 from a subset of subjects 1
2 Statistical Methods: Analysis Populations: Enrolled subjects: Subject who signed an informed consent form and were assigned a Patient Identification number (PID) Randomized subjects: Enrolled subjects who received a treatment assignment from the interactive voice response system (IVRS) Treated subjects: Randomized subjects who received at least 1 dose of /GSK or EFV Modified Intent to Treat Analysis Set [mitt]): All randomized subjects who received at least 1 dose of BMS /GSK or EFV. Observed analysis set: A collection of subjects that have data within an interval of interest. Evaluable PK population: all treated subjects who have adequate PK profiles Statistical Analysis: In general, categorical variables were tabulated with counts and percents. Continuous variables were summarized with univariate statistics (eg, mean, median, standard error). Longitudinal analyses use pre-defined visit week windows. Unless otherwise specified, windows around planned measurement times are constructed based on the midpoint between planned study visits (ie, half the duration of time between study visits), and data are summarized at each scheduled visit. For the calculation of descriptive statistics of observed data, subjects must have a baseline measurement to be evaluable for longitudinal tabulations of parameter values and changes from baseline. Tabulations of the following endpoints present the number of unique subjects with an event: protocol deviations; interruptions of study therapy; non-study medications; adverse events; and laboratory abnormalities. Thus, multiple occurrences of the same event are counted only once per subject. Efficacy Analyses The efficacy analyses were based on the treated subjects. Primary Efficacy Analysis(es) The primary efficacy endpoint is the proportion of subjects with plasma HIV-1 RNA < 4 c/ml at the Week 24 snapshot. This endpoint is assessed with the FDA snapshot algorithm. The primary analysis was based on a modified ITT (mitt) approach. A sensitivity analysis was conducted using an observed values approach. Response rates were tabulated by treatment arm with exact binomial 95% confidence intervals. Subgroup summaries were provided to examine the impact of baseline viral load and HIV-1 Clade AE (Clade AE versus Other) for both the mitt and the observed values approach. Secondary Efficacy Analysis(es) The secondary endpoints were summarized by treatment arm. Pharmacokinetic Analyses at Week 2 Geometric means and coefficients of variation (CV) were presented for maximum concentration (Cmax), area under the concentration time curve over one dosing interval [AUC(TAU)], the pre-dose plasma concentration (C), and the plasma concentration at the end of one dosing interval (i.e. 24 hours post-dose, Ctau). Medians and ranges were presented for the time of maximum plasma concentration (Tmax). Study Population: Men and non-pregnant women, at least 18 years of age who were antiretroviral treatment-naïve (defined as no current or previous exposure to >1 week of an antiretroviral drug) with plasma HIV-1 RNA 1 c/ml and CD4 T-cell count >2 cells/cubic millimetre (mm 3 ) were included in the study. Subjects with resistance or partial resistance to any study drug; current or historical genotypic and/or phenotypic drug resistance testing showing resistance to EFV, tenofovir (TDF), emtricitabine (FTC), certain thymidine analog mutations (TAMs) and certain protease inhibitor (PI) mutations; positive hepatitis B virus (HBV)/hepatitis C virus (HCV) were excluded from the study. 6 mg+ 12 mg+ 18 mg+ EFV 6 mg+ Number of Subjects: Planned Randomised, N Total Number Subjects Withdrawn, 1 (19.2) 11 (2.8) 1 (19.2) 1 (18.9) N (%) Withdrawn due to Adverse Events 3 (5.7) 5 (9.6) 9 (17.) n (%) Withdrawn due to Lack of Efficacy 3 (5.8) 4 (7.5) 2
3 n (%) Withdrawn for other reasons n (%) 6 (11.5) 4 (7.5) 5 (9.6) Demographics EFV 6 mg+ 6 mg+ 12 mg+ 18 mg+ N (mitt) Females: Males 8:42 8:44 7:44 7:46 Mean Age, years (SD) White, n (%) 31.8 (8.26) 39 (78.) 34.7 (11.29) 38 (73.1) 35.5 (11.34) 41 (8.4) 32.9 (9.35) 4 (75.5) Primary Efficacy Results: Proportion of Responders (HIV-1 RNA <4 c/ml) at Week 24 Snapshot (mitt) 6 mg+ N=5 12 mg+ 18 mg+ EFV6 mg+ HIV-1 RNA <4 c/ml a, n (%) [95% 38 (76.) [ (82.7) [ (82.4) [ (77.4) confidence interval] 86.9] 91.8] 91.6] [ ] HIV-1 RNA >=4 c/ml, n (%) 1 (2.) 7 (13.5) 4 (7.8) 3 (5.7) No Virologic data in window, n (%) 2 (4.) 2 (3.8) 5 (9.8) 9 (17.) a=response was assessed with the snapshot algorithm, which used the last plasma HIV-1 RNA value in the predefined visit window to classify a subject's response status. Secondary Outcome Results: Proportion of Responders (HIV-1 RNA <2 c/ml) at Week 24 Snapshot (mitt) 6 mg+ N=5 12 mg+ 18 mg+ EFV 6 mg+ HIV-1 RNA <2 c/ml a, n (%) 4 ( 8.) 44 (84.6) 43 (84.3) 44 (83.) HIV-1 RNA >= 2 c/ml, n (%) 8 (16.) 6 (11.5) 2 (3.9) No Virologic data in window, n (%) 2 (4.) 2 (3.8) 6 (11.8) 9 (17.) a = Response was assessed with the snapshot algorithm, which used the last plasma HIV-1 RNA value in the predefined visit window to classify a subject's response status. Newly Emergent Genotypic Resistance Profile (mitt) 6 mg+ N=5 12 mg+ 18 mg+ EFV 6 mg+ Underwent resistance testing n (%) 5 (1) 6 (1) 4 (1) 1 (1) Sequenced 5 (1) 5 (83.3) 2 (5) 1 (1) RT Substitution 3 (6) 5 (1) 2 (1) NRTI substitutions 3 (6) 5 (1) 2 (1) K65K/R 1 (5) K7K/E 1 (2) M184 3 (6) 5 (1) 2 (1) I 1 (2) 1 (2) I/V 1 (2) V 2 (4) 3 (6) 2 (1) NNRTI substitutions 1 (2) 1 (2) V16V/I 1 (2) E138E/G 1 (2) Summary Statistics for Change from Baseline Over Time in HIV-1 RNA (log1 c/ml) Mean (SD) EFV 6 mg+ 6 mg+ 12 mg+ 18 mg+ N=5 Pre-treatment (Baseline) (.6689) (.7289) (.682) (.7295) 3
4 absolute value Changes from Baseline: Mean (SD) Mean (SD) Mean (SD) Mean (SD) Week 4: Day (.587) (.5382) (.593) (.4597) Week 8: Day (.6995) (.796) (.641) (.642) Week 12: Day (.8221) (.7584) (.6373) (.6252) Week 16: Day (.8656) (.7964) (.6426) (.699) Week 24: Day (.813) (.7937) (.7279) (.7586) Week 32: Day (.839) (.7349) (.6551) (.7542) Week 4: Day (.5622) (.5992) (.5465) (.7215) Week 48: Day (.676) (.5144) (.678) (.598) Summary Statistics for Change from Baseline Over Time in CD4 Cell Count (cells/microliter [µl]) Mean (SD) 6 mg+ N=5 12 mg+ 18 mg+ EFV 6 mg+ Screening (Baseline) absolute (232.15) 46.6 (214.5) (182.98) (162.72) value Changes from Baseline: Mean (SD) Mean (SD) Mean (SD) Mean (SD) Week 4: Day (148.92) 71.5 (169.22) 52.9 (149.54) 71.1 (145.1) Week 8: Day (219.64) 8.4 (127.52) 88.4 (177.68) (23.74) Week 12: Day (17.87) (179.42) (175.73) (118.39) Week 16: Day 113 Week 24: Day (2.76) 94.3 (175.) 98.4 (173.53) 79.7 (199.46) 128. (212.9) 92.5 (144.4) 14.5 (179.7) (151.7) Week 32: Day 225 Week 4: Day (19.12) (161.74) 96.2 (167.77) (25.51) 97.7 (174.75) (219.4) (148.97) (161.7) Week 48: Day (15.21) (13.27) 28.7 (9.61) 289. (244.9) Safety Results: An on therapy AE was defined as an AE with onset on or after the start date of study medication but not later than one day after the last date of study medication. An on therapy serious adverse event (SAE) was defined as a SAE with onset on or after the start date of study medication and up to 3 days after the last dose of medication. EFV 6 mg+ 6 mg+ 12 mg+ 18 mg+ N=5 Subjects with any AEs, n(%) 41 (82.) 45 (86.5) 45 (88.2) 48 (9.6) Subjects with any AEs leading 1 (2.) 3 (5.8) 4 (7.8) 9 (17.) to discontinuation of study drug, n(%) Most Frequent Adverse Events n (%) n (%) n (%) n (%) On-Therapy Diarrhoea 19 (38.) 19 (36.5) 31 (6.8) 6 (11.3) Abdominal pain Nausea 4 (8.) 3 (6.) 5 (9.6) 4 (7.7) 11 (21.6) 6 (11.8) 7 (13.2) Vomiting 2 (4.) 5 (9.6) 3 (5.9) Abdominal pain upper 3 (6.) 3 (5.8) 4 (7.8) Dyspepsia 5 (9.6) 1 (2.) Pharyngitis Upper respiratory tract infection 5 (1.) 3 (6.) 3 (5.8) 6 (11.5) 2 (3.9) 2 (3.9) 3 (5.7) Influenza 2 (4.) 5 (9.6) 1 (2.) 3 (5.7) 4
5 Nasopharyngitis 3 (6.) 3 (5.8) 4 (7.8) Sinusitis 3 (6.) 1 (2.) Conjunctivitis Dizziness 3 (6.) 2 (3.8) 2 (3.9) 19 (35.8) Headache 3 (5.8) 4 (7.8) 6 (11.3) Insomnia 1 (2.) 8 (15.7) 2 (3.8) Abnormal dreams 4 (7.7) 1 (2.) 5 (9.4) Fatigue Back pain 3 (6.) 1 (2.) 3 (5.9) 4 (7.8) Serious Adverse Events - On-Therapy n (%) [n considered by the investigator to be related to study medication] 6 mg+ N=5 12 mg+ 18 mg+ EFV 6 mg+ Subjects with non-fatal SAEs, n (%) [related] 1 (2.) 2 (3.8) [1] 1 (2.) 5 (9.4) [1] Abdominal pain Colitis Ulcerative 1 (2.) [1] Toothache Intervertebral discitis Urinary tract infection 1 (2.) Ventricular extrasystoles Overdose Hepatic enzyme increased [1] Pneumothorax spontaneous Subjects with fatal SAEs, n (%) CDC Class C AIDS Events 6 mg+ N=5 12 mg+ 18 mg+ EFV 6 mg+ Oesophageal Candidiasis Pharmacokinetic Results for /GSK at Week 2: 6 mg+ 12 mg+ 18 mg+ Cmax (ng/ml) Tmax (h) Median [n] (Min-Max) AUC(TAU) (ng.h/ml) C (ng/ml) Ctau (ng/ml) 1945 [8] (16) 4. [8] ( ) [8] (19) 165 [8] (25) 11 [9] (15) 3162 [6] (29) 4.29 [6] ( ) [6] (33) 181 [6] (33) 1657 [6] (4) 4645 [1] (16) 5.5 [1] (1.-12.) [1] (21) 2729 [1] (18) 276 [1] (27) Conclusion: Overall, 76% to 82.7% of subjects on /GSK treatment arms and 77.4% of subjects on EFV treatment arm had HIV-1 RNA < 4 c/ml at Week 24 (mitt snapshot algorithm). Although the efficacy of /GSK and 18 mg arms was similar to the EFV reference arm, a relatively higher and unacceptable rate of GI intolerability and higher rate of NRTI resistance was observed across all three BMS /GSK treatment arms. In 6 mg+ group, 41 subjects were reported with AEs with the most frequently reported being diarrhoea and pharyngitis. In 12 mg+ group, 45 subjects were reported with AEs with the most frequently reported being 5
6 diarrhoea and upper respiratory tract infection. In 18 mg+ group, 45 subjects were reported with AEs with the most frequently reported being diarrhoea and abdominal pain. In EFV 6 mg+ group, 48 subjects were reported with AEs with the most frequently reported being dizziness and nausea. One subject each in 6 mg+ and 18 mg+ groups were reported with non-fatal SAEs; 2 subjects in 12 mg+ group and 5 subjects in EFV 6 mg+ group were reported with non-fatal SAEs. There were no fatal SAEs reported in the study. Based upon the AI468-38/25891 Week 24 primary endpoint analysis, it was determined that BMS /GSK was not optimal for Phase 3 development due to GI intolerability and treatment-emergent resistance, and the compound will not be advanced into planned Phase 3 studies. 6
GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:
GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBristol-Myers Squibb
A Study of the Safety and Efficacy of plus Tenofovir in Adults with Chronic Hepatitis B Virus Infection with Previous Nucleoside/Nucleotide Treatment Failure () FINAL CLINICAL STUDY REPORT EUDRACT Number:
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationIndividual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424138
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Atazanavir () Individual Study Table Referring to the Dossier (For National Authority Use Only)
More informationCabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results
Slide 1 Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results David A. Margolis, 1 Juan Gonzalez-Garcia, 2 Hans-Jürgen Stellbrink, 3 Joe Eron, 4 Yazdan Yazdanpanah, 5 Sandy
More informationIntroduction. Cahn et al. Andean Pacific HIV Clinical Forum 2017; Santiago, Chile. Abstract 2.
Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed Dose Combination (FDC) Compared With Ritonavir- Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in
More informationFinal Clinical Study Report. to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI463110
BMS-475 AI463 Name of Sponsor/Company: Bristol-Myers Squibb Individual Study Table Referring to the Dossier For National Authority Use Only) Name of Finished Product: Baraclude Name of Active Ingredient:
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationABT-493/ABT-530 M Clinical Study Report Post-Treatment Week 12 Primary Data R&D/16/0162. Referring to Part of Dossier: Volume: Page:
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-493/ABT-530 Name of Active Ingredient: ABT-493: (3aR,7S,10S,12R,21E,24aR)- 7-tert-butyl-N-{(1R,2R)-2- (difluoromethyl)-1-[(1- methylcyclopropane-1- sulfonyl)carbamoyl]cyclopropyl}-20,20-
More informationIndividual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424136
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationmg 25 mg mg 25 mg mg 100 mg 1
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s):
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThis was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPurpose Methods Demographics of patients in the study Outcome. Efficacy Adverse Event. Limitation
ANDREW LEE Purpose Methods Demographics of patients in the study Outcome Efficacy Adverse Event Limitation Dolutegravir Integrase inhibitor Plasma half life 14hours Tivicay FDA (US)- 13 August 2013 50mg
More informationDidactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016
Didactic Series CROI 2016 - New Antiretroviral Therapies Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 This project is supported by the Health Resources and
More informationMedian (Min Max) CVC 100 mg + EFV placebo + TDF/FTC (N=8) CVC 200 mg + EFV placebo + TDF/FTC (N=10) LLOQ=5.00 ng/ml Time (h)
600 Pharmacokinetics (Pk) of cenicriviroc (cvc) following 100 or 200 mg once-daily Dosing with open-label tenofovir / emtricitabine (tdf/ftc) in hiv-1 infected subjects enrolled in a Phase 2b study David
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationNEXT GENERATION DIRECT-ACTING ANTIVIRALS
EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN PATIENTS CO-INFECTED WITH HEPATITIS C VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS-1: THE EXPEDITION-2 STUDY J. Rockstroh, K. Lacombe, R. Viani, C. Orkin, D.
More informationClinical Study Report AI Final 28 Feb Volume: Page:
Study Design, Continued Electrocardiogram (ECG) and vital sign assessments were done at select times during the study. Blood and urine samples for clinical laboratory evaluations were collected at specified
More informationSubjects from the Safety Population who had GSK PK parameter estimates from any portion of the study. Cohort 1 (N=8)
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics>
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-333 Volume: Name of Active Ingredient: Page: Sodium N-{6-[3-tert-butyl-5-(2,4-
More informationGSK Medication: Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationABT-493/ABT-530 M Clinical Study Report Post-Treatment Week 12 Primary Data R&D/16/0144. Referring to Part of Dossier: Volume: Page:
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-493/ABT-530 Name of Active Ingredient: ABT-493: (3aR,7S,10S,12R,21E,24aR)- 7-tert-butyl-N-{(1R,2R)-2- (difluoromethyl)-1-[(1- methylcyclopropane-1- sulfonyl)carbamoyl]cyclopropyl}-20,20-
More informationCabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016
Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team RPV CAB CAB RPV 1 June 2016 Cabotegravir Long-Acting Nanosuspension CAB is an investigational
More informationPediatric Patient Information:
New pediatric dosing information for Aptivus, patients 2-18 years of age, approval of New Oral Solution and information on coadministration with midazolam Aptivus (tipranavir) is now available as an oral
More informationDTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone
DTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone Aboud M, 1 Brites C, 2 Lu H, 3 Supparatpinyo K, 4 Hercilla L, 5 Sievers J, 1 Nascimento MC, 1 Hopking J, 6 Underwood
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEfficacy and Safety of Doravirine 100mg QD vs Efavirenz 600mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results
Efficacy and Safety of Doravirine 1mg QD vs Efavirenz 6mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results Jose M. Gatell, Francois Raffi, Andreas Plettenberg, Don Smith, Joaquin Portilla,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study
Study No.: ADF105220 Title: Phase III study of adefovir dipivoxil () tablets in patients with compensated chronic hepatitis B -comparative study against lamivudine ()- Rationale: This study wass a confirmatory
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAnalysis of safety The analysis was performed on the Total Vaccinated cohort.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe results of the ARTEN study. Vicente Soriano Hospital Carlos III, Madrid, Spain
The results of the ARTEN study Vicente Soriano Hospital Carlos III, Madrid, Spain Nevirapine: a well-defined efficacy and tolerability profile High efficacy levels 1 3 Well-defined safety profile 4 Favourable
More informationIAC Analyst Presentation
IAC Analyst Presentation David Redfern Chairman, ViiV Healthcare Chief Strategy Officer, GSK July 27, 2012 1 ViiV Healthcare Dr Dominique Limet CEO, ViiV Healthcare July 27, 2012 2 Equity split of 85%
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationVIKING STUDIES. Efficacy and safety of dolutegravir. treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir treatment-experienced subjects (DTG) in UK/DLG/0083/14e(2) Date of preparation: February 2017 Prescribing information is available at the end of this
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Clinical Study Report IM Double-blind Period
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier SYNOPSIS (For National Authority
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAbstract PS8/2. Double-blind treatment phase D/C/F/TAF. + matching D/C + F/TDF placebo D/C/F/TAF. D/C + F/TDF + matching D/C/F/TAF placebo
WEEK 8 RESULTS OF AMBER: A PHASE 3, RANDOMISED, DOUBLE-BLIND TRIAL IN ANTIRETROVIRAL TREATMENT (ART)-NAÏVE HIV--INFECTED ADULTS TO EVALUATE THE EFFICACY AND SAFETY OF THE ONCE-DAILY, SINGLE-TABLET REGIMEN
More informationAnalysis of immunogenicity
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No: Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods: Sample Size
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSECONDARY OBJECTIVES:
Study No.: 112 419 Title: Retrospective study using the NADIS database of the reasons for discontinuing the Abacavir-Lamivudine combination in HIV-infected patients treated by an antiretroviral regimen
More informationReports of efficacy and safety studies of primary immunodeficiency
2. SYNOPSIS TITLE OF STUDY: Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of IGIV3I GRIFOLS [Immune Globulin Intravenous (Human)] for Replacement Therapy in Primary Immunodeficiency
More informationStudy No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy Centers: This study was conducted in 2 centers in Italy.
Title of Trial: A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationTitle A Phase II study of oral LBH589 in adult patients with refractory cutaneous T-Cell lymphoma
Sponsor Novartis Generic Drug Name Panobinostat Therapeutic Area of Trial Refractory cutaneous T-Cell lymphoma Approved Indication Investigational drug Protocol Number CLBH589B2201 Title A Phase II study
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationViiV Healthcare Investor and Analyst Update 24 July 2018
ViiV Healthcare Investor and Analyst Update 24 July 2018 Cautionary statement regarding forward looking statements This presentation may contain forward-looking statements. Forward-looking statements give
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSponsor Novartis. Generic Drug Name Pasireotide. Therapeutic Area of Trial Cushing s disease. Protocol Number CSOM230B2208E1
Sponsor Novartis Generic Drug Name Pasireotide Therapeutic Area of Trial Cushing s disease Protocol Number CSOM230B2208E1 Title Extension to a multicenter, open-label study to assess the safety and efficacy
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More informationABT-493/ABT-530 M Clinical Study Report Post-Treatment Week 12 Primary Data R&D/16/0145. Referring to Part of Dossier: Volume: Page:
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-493/ABT-530 Name of Active Ingredient: ABT-493: (3aR,7S,10S,12R,21E,24aR)- 7-tert-butyl-N-{(1R,2R)-2- (difluoromethyl)-1-[(1- methylcyclopropane-1- sulfonyl)carbamoyl]cyclopropyl}-20,20-
More informationFrailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi
Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting Giovanni Guaraldi Potential conflicts of interest Research funding: Jansen, Gilead, MSD, BMS Consultancies:
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHydrocodone/Acetaminophen Extended-Release Tablets M Clinical Study Report R&D/09/1109
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-712 Volume: Hydrocodone/Acetaminophen Extended-Release Name
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTreatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand
Treatment experience in South Africa Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Overview South African Prevalence Adherence Combination ddi + d4t Nevirapine Hepatotoxicity
More informationv Dr Anton Pozniak Chelsea and Westminster Hospital, London Injectable ARVs a S.W.O.T Analysis
18 th Annual Resistance and Antiviral Therapy Meeting v Dr Anton Pozniak Chelsea and Westminster Hospital, London Thursday 18 September 2014, Royal College of Physicians, London Injectable ARVs a S.W.O.T
More informationDolutegravir Attributes
Dolutegravir (; S/GSK1349572) in Combination Therapy Exhibits Rapid and Sustained Antiviral Response in Antiretroviral Naïve Adults: 96 Week Results from SPRING 1 (ING112276) Hans Juergen Stellbrink, 1
More informationDevelopment of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir
Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide () Bryan Baugh 1, Erika Van Landuyt 2, Simon Vanveggel 2, Herta
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationUMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationSecondary efficacy endpoints for Part 2, the Eltrombopag-Only Period, included the proportion of subjects who
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information2.0 Synopsis. ABT-450/r, ABT-267 M Clinical Study Report R&D/17/0539. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-450, ritonavir, ABT-267, ribavirin, pegylated interferon Name of Active Ingredient: ABT-450, Ritonavir, ABT-267, Ribavirin, Pegylated interferon Individual
More information